Several angiogenesis inhibitors such as sorafenib, sunitinib, pazopanib, vandetanib, axitinib, cediranib and bevacizumab are either in final stages of their development or have been approved as anticancer drugs by FDA.
The protein kinase inhibitor imatinib has been approved as an efficient anticancer drug with common but mild cutaneous toxicities.
Sirolimus, also known as rapamycin, is the prototype mTOR inhibitor it is a natural compound that initially was approved as an immunosuppressant for organ transplantation but also is known for its antifungal and anticancer activities.
Federal officials said it was apparently the first anticancer drug to be approved for people who do not have the disease.
23, 24 The Jak2-specific inhibitor ruxolitinib has been approved for myelofibrosis as an anticancer drug that targets the Jak STAT pathway.
TOR kinase is inhibited by rapamycin, a natural macrolide compound isolated from bacteria, analogs of which are approved for human use as immunosuppressants and in anticancer therapy (Guertin and Sabatini, 2009; Hartford and Ratain, 2007).
Ulipristal acetate (UPA) is approved for use as an emergency contraceptive pill, but no SPRM is approved for regular contraception.
Importantly, rapamycin analogs have already been approved for human use as immunosuppressant drugs and are currently under clinical trials for use as anticancer agents (Guertin and Sabatini, 2009).
First of all, the evaluation only pertains to anticancer drugs approved by EMEA following the centralised procedure and it must be borne in mind that some important anticancer drugs such as gemcitabine were approved in Europe during the study period using alternative regulatory procedures.
